Ampersand Capital Partners Acquires Purna Pharmaceuticals

Ampersand Capital Partners has acquired Purna Pharmaceuticals, a provider of development and manufacturing services for liquid and semi-solid dosage forms for pharmaceutical customers. The deal is positioned as a growth platform investment in life sciences and healthcare services.

Ampersand says the acquisition creates opportunities for collaboration with MedPharm, its topical and transdermal pharmaceutical development and manufacturing platform, to serve global clients as a trans-Atlantic provider of topical and transdermal drug products. Purna is described as an independent Belgian company established in 1986, supporting GXP-standard contract manufacturing for semi-solid, powders, and liquid pharmaceutical products.

Achelous Partners acted as investment banking and financial advisor to Purna in the transaction.